NEW TECH FOODS

Multus Biotechnology has introduced Proliferum P, the first commercially available animal component-free (ACF) serum replacement formulated specifically for porcine adipose-derived stem cells (ASCs).

Developed using Multus’ AI-driven media optimisation platform, the product supports ASC growth while maintaining key characteristics such as stemness and adipogenic differentiation. ASCs are used in regenerative medicine, therapeutic research and cultivated meat production due to their ability to differentiate into fat, bone and cartilage.

The new formulation offers a cost-effective, scalable alternative to fetal bovine serum (FBS), traditionally used in cell culture. Multus claims Proliferum P matches or outperforms FBS, addressing performance, consistency and ethical concerns associated with animal-derived components.

Soraya Padilla, project lead for Proliferum P, said: "Traditional approaches typically take two to four years to develop serum replacements. Using our proprietary media optimisation platform, we’ve designed Proliferum P specifically for porcine adipose-derived stem cells."

"By combining high-throughput lab automation, AI, and our unique insights in complex ingredient interactions and cell biology, we’ve built a process that not only accelerates the media development process but also customizes it to specific cell types."

Cai Linton, co-founder and CEO of Multus, added: "Our platform doesn't just allow us to match industry standards – it ensures we continuously raise the bar. With Proliferum P, we're delivering a superior product to FBS while demonstrating how AI and automation, in the hands of our experienced scientists, can transform biotechnology development timelines."

Top image: © Multus Biotechnology